Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

While reporting financial results for the fourth quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) initiated its earnings, ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Goldberg said the company "melded" a CBS News Sunday Mornings appearance from her to sell “bad weight loss drugs." ...

The EGOT winner railed against an ad that's circulating on social media with a manipulated version of her promoting "bad ...

Whoopi Goldberg took to The View to blast a "phony" AI weight loss ad running on social media that is using her image to ...

Previously, the drugs were able to be prescribed through an email chat, from questionnaires or by people sending in photos of ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NYSE: NVO) is under pressure from investors for more information about its ...